Analyst recommendations for Boston Scientific
In this part, we’ll take a look at Wall Street analyst recommendations and target prices for Boston Scientific (BSX) stock over the next 12 months. Based on the recommendations of 27 brokerage firms in a Bloomberg survey, about 78% gave Boston Scientific a consensus rating of “buy.” About 22% rated it a “hold,” and none of the analysts rated Boston Scientific a “sell.”
The above table lists the 19 brokerage firms that provided a target price for Boston Scientific for the next 12 months. The consensus 12-month target price is $27.6, amounting to about a 16.2% return potential. This compares to its price of $23.7 on September 26, 2016.
According to the latest ratings provided by Jefferies, Boston Scientific has a one-year target price of $24, the lowest target price of all the analysts. This target implies a 1.1% return over the next 12 months.
Among the large investment banks, J.P. Morgan gave Boston Scientific a one-year target price of $27, which implies about a 13.8% return potential over the next 12 months. Brokerage firm Argus Research gave the stock its highest one-year target price of $33, which implies a return of ~39%.
Peers Edwards Lifesciences (EW), Medtronic (MDT), and Baxter (BAX) have average broker target prices of $124.6, $94.7, and $50.4, respectively. These figures imply returns of 4.8%, 10%, and 6.8%, respectively, in the next 12 months.
You can get exposure to Boston Scientific and its peers by investing in the iShares US Medical Devices (IHI). IHI holds approximately 4.6%, 3.9%, 12.6%, and 3.6% of its total holdings in Boston Scientific, Edwards Lifesciences, Medtronic, and Baxter, respectively.